PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

Abstract Background Management of bladder cancer (BLCA) has not changed significantly in the past few decades, with platinum agent chemotherapy being used in most cases. Chemotherapy reduces tumor recurrence after resection, but debilitating toxicities render a large percentage of patients ineligibl...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Sayani Bhattacharjee, Matthew J. Sullivan, Rebecca R. Wynn, Alex Demagall, Andrew S. Hendrix, Puneet Sindhwani, Firas G. Petros, Nagalakshmi Nadiminty
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2022-03-01
Serie:	BMC Cancer
Soggetti:	Bladder cancer Urothelial carcinoma PARP inhibition Cisplatin DNA damage repair Combination therapy
Accesso online:	https://doi.org/10.1186/s12885-022-09376-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!